Overexpression of a membrane transport system MSMEG_1381 and MSMEG_1382 confers multidrug resistance in *Mycobacterium smegmatis*.

S Salini[1][$], Balaji, Muralikrishnan[1,2][$], Sinchana G Bhat[1][$], R Ajay Kumar[1], and Krishna Kurthkoti[1*]

[1] Mycobacterium Research Laboratory, Rajiv Gandhi Centre for Biotechnology, Thiruvananthapuram 695014.

[2] Present address: Department of Biology, Indian Institute of Science Education and Research, Tirupati 517507

[$] Contributed equally to the work

* Address correspondence to: Krishna Kurthkoti; kurthkoti@rgcb.res.in; +91 0471 2529519

Running title: Drug resistance in persister mycobacterial cells

Keywords: Drug resistance, Efflux pump, Tet[R] transcriptional regulator, Mycobacteria, MmpL

Abstract

1

Mycobacterium tuberculosis is a leading cause of human mortality worldwide and the emergence of drug-resistant strains, demands the discovery of new classes of antimycobacterials that can be employed in the therapeutic pipeline. Previously, a secondary metabolite Chrysomycin A, isolated from *Streptomyces* sp. OA161 was shown to have potent bactericidal activity against drug-resistant clinical isolates of *M. tuberculosis* and different species of mycobacteria. The antibiotic inhibits the mycobacterial topoisomerase I and DNA gyrase leading to bacterial death, but the mechanisms that could cause resistance are currently unknown. To further understand the resistance mechanism, spontaneous resistance mutants were isolated and subjected to whole-genome sequencing. Mutation in a Tet[R] family transcriptional regulator MSMEG_1380 was identified in the resistant isolates and was close to an operon encoding membrane protein MSMEG_1381 and MSMEG_1382. Sequence analysis and modeling studies indicated that they are components of the Mmp family of efflux pumps and over-expression of either the operon or individual genes conferred resistance to chrysomycin A, isoniazid, and ethambutol that are in TB therapy. Our study highlights the role of membrane transporter proteins in conferring multiple drug resistance and the utility of recombinant strains overexpressing membrane transporters in the drug screening pipeline.

Introduction

The emergence of antimicrobial resistance (AMR) in bacterial pathogens worldwide is a major health concern. Declaration by the World Health Organization (WHO) that AMR is a

global health threat requiring urgent action is a testimony to this emerging crisis (1). *Mycobacterium tuberculosis* is the causative agent of tuberculosis and a leading cause of debilitation and mortality in humans. Emergence of drug resistant TB strains is a global health concern and further prolongs the duration and expenditure of treatment. The complex lipid-rich cell wall of mycobacteria serves as a natural barrier for entry of drugs, and the presence of efflux pumps further enhances the antibiotic resistance repertoire in *Mycobacterium*. Efflux pumps in bacteria are proteins embedded in the plasma membrane, whose function is to regulate the internal environment by removing toxic substances, including quorum-sensing signal molecules, metabolites, and antimicrobial agents. There are five major families of efflux transporters in prokaryotes based on their structural morphologies and similarities, energy sources, and substrates (2, 3).

Bioinformatic analysis predicted the presence of at least 26 complete ATP-binding cassette superfamily (ABC) transporters and 16 major facilitator superfamily proteins in *M. tuberculosis* genome and have been shown to be involved in the transport of antibiotics; many which are used in treatment (4, 5). Among five major families of efflux transporter, the Resistance-Nodulation-Division (RND) protein is found in all kingdoms of living organisms. It can mediate the transport of a wide range of substrates, including heavy metals, aliphatic and aromatic solvents, bile salts, fatty acids, detergents, and dyes. In *Escherichia coli* and *Pseudomonas aeruginosa*, the RND family proteins play an important role in antibiotic resistance (6).

Overexpression of efflux pump is an efficient mode of attaining pleiotropic drug resistance in mycobacteria resulting from expression of a diverse group of proteins such as RND and, ABC transporters (15–18). Genes encoding the RND family of transporters are identified in *Mycobacterium* species and are named MmpL (**m**ycobacterial **m**embrane **p**rotein **l**arge) (7, 8). Several studies have demonstrated that the overexpression of efflux pump genes in MDR and XDR clinical strains increases resistance to antibiotics (9, 10). The Mmp family of proteins is often expressed as an operon and codes for a smaller protein

3

(MmpS) and a larger protein (MmpL). They are found in close association with polyketide synthetic gene cluster and have been implicated in diverse functions such as exporting lipid molecules and siderophores across the bacterial envelope and conferring antibiotic resistance (8, 11–13). The smaller protein MmpS5 is a membrane fusion protein that works as a crucial auxiliary protein of MmpL5. The homotrimeric assembly of the MmpL5 monomers in the inner membrane with the assistance MmpS5 complex is shown to be crucial in the virulence of *M. tuberculosis*, rendered by the siderophore-facilitated iron acquisition (14). The occurrence of the Mmp proteins in mycobacteria varies, with the lowest of 9 members present in *M. leprae* to around 58 in *M. abscessus* (15). In mycobacteria, the *mmp* operon is often regulated by one the most abundant regulators-the Tet^R family of regulators (TFR). The TFRs are and often expressed divergently to the *mmp* operon and contain a Helix-turn-helix (HTH) DNA binding motif at the N-terminal. They generally function as repressors, but in a few exceptional cases can be activators of gene expression (16–18).

We have earlier reported that Chrysomycin A, an antibiotic isolated from *Streptomyces* sp. OA161 possesses potent antimycobacterial activity and effectively killed drug-resistant strains of *M. tuberculosis* (19, 20). In the present study, we report a novel role for MmpL5 and Mmps5 complex in conferring resistance to chrysomycin A. Through a forward genetics approach, we isolated and characterized chrysomycin A resistant mutants by whole genome sequencing. Our analysis identified mutation in MSMEG_1380, a TetR family of transcriptional regulators that regulates a divergently transcribed operon MSMEG_1381 and MSMEG_1382 (*mmpS5* and *mmpL5*, respectively) that constitute an operon involved in membrane transport in mycobacteria. Overexpression of *mmpS5* and *mmpL5* either alone or as an operon resulted in increased resistance to chrysomycin and other antitubercular drugs such as isoniazid, ethambutol, and rifampicin. Our finding has uncovered an auxiliary role of membrane transport protein in multiple antibiotic resistance, further expanding the list of candidates linked to AMR in mycobacteria.

Results

Isolation and whole-genome sequence analysis of chrysomycin resistant mutants of

M. smegmatis

Chrysomycin A displays potent antimycobacterial activity, and our recent study has shown its bactericidal activity emanates from inhibition of topoisomerase I and DNA gyrase (20). It therefore, became necessary to further understand the mechanisms of resistance to this potential antibiotic. We employed an unbiased forward genetics approach by isolating spontaneous chrysomycin A resistant mutants and identified the mutations by whole-genome sequencing. A similar approach has been exploited to identify novel modes of resistance in mycobacteria and the specific antibiotic target (21). Randomly selected 50 chrysomycin A resistant colonies were patched on fresh 7H10 chrysomycin A (2X the MIC) plates to reconfirm that the colonies were true resistant strains and could grow in the presence of antibiotics. A set of ten isolated colonies (isolate 12, 18, 21-25, 45, 43, and 51) and the parental *M. smegmatis* strain were inoculated in plain 7H9 medium. No observable growth was seen in isolates 12, 18, 51, however the other isolates that managed to grow showed severe clumping and did not exceed mid-log-phase (O.D$_{600}$ ~ 0.5). Whole-genome sequence analysis of the parental and the three resistant colonies isolates 21, 24 and 42 revealed 77 variants in isolates 21 and 24 and 102 variants in isolate 42, with the majority of variants being SNPs (Supplementary xl sheet 1-3). The variants were not identical in all the isolates, indicating that the colonies subjected to genome sequencing were not clones. The mutations identified in different isolates mapped to DNA binding protein (*bm3R1*), DNA polymerase IV (*dinB1*) and phosphoglucosamine mutase (*glmM*) (Table-1). Interestingly, mutation was observed in *bm3R1* among all the isolates and was therefore selected for further analysis.

Resistant strains of chrysomycin A contain mutations in MSMEG_1380, a Tet^R regulator of *Mycobacterium smegmatis*

BLAST analysis of the DNA sequence corresponding to the DNA sequence annotated as *bm3R1* gene (Prokka database) was identified as *MSMEG_1380*. The gene is annotated as a Tet^R family transcriptional regulator and is adjacent to an operon consisting of two genes,

5

MSMEG_1381, and *MSMEG_1382.* The organization of *MSMEG_1380, MSMEG_1381,* and *MSMEG_1382* in the *M. smegmatis* indicated that the *MSMEG_1380* is divergently transcribed compared to the other genes (Fig.1A). Alignment of the DNA sequence of *MSMEG_1380* from the resistant colonies with the wild-type sequence revealed that isolate 21 had a frameshift. In contrast, isolates 24 and 42 had an in-frame duplication of 6 nucleotides within the open reading frame (Fig. 1B). Protein alignment of the translated sequence revealed that the insertion of a single nucleotide results in frame shift resulting in a change of amino acid Glu at position 5 and further leads to premature termination of the protein in isolate 21. In the case of isolates 24 and 42 we observed an in-frame duplication of amino acid Val and Gly at 50th and 51st positions, respectively. *In silico* modeling of MSMEG_1380 revealed that the protein shares structural homology to the TetR family of transcription regulators.

Interestingly, the modeling results predicted that the duplication of Val and Gly resulted in distorted interaction with the DNA (palindromic sequence found upstream of MSMEG_1380). At the same time, this interaction to both the strands of DNA was lost in the mutant 24 and 42 (the inclusion of additional Gly and Val resulted in distortion of the yellow and orange helices which were interacting in the wild-type protein) (Fig. 2A panels i and ii). We speculated that the distortion caused by duplication of residues 49 and 50 could negatively impact the DNA binding and affect regulatory functions of the protein. In-frame insertion of amino acids in transcriptional regulators have been previously reported in Rv0678, that regulates the expression of *mmpS5~mmpL5* operon in *M. tuberculosis* and resulted in reduced DNA binding leading to de-repression of the operon (21, 22). We believe that mutations observed in the TetR regulator *MSMEG_1380* could have similar effects on the expression of the adjacent genes *MSMEG_1381* and *MSMEG_1382.*

Overexpression of MmpL5 alone or as an operon causes growth defects

The open reading frames *MSMEG_1381* and *MSMEG_1382* are predicted to be involved in membrane transport and code for MmpS5 and MmpL5, respectively.

Transmembrane domain analysis of the primary sequence indicated that the MmpL contains 11 transmembrane domains which is in agreement with its predicted membrane localization (Fig.2B-C). The membrane proteins MmpS4/MmpL4 and MmpS5/MmpL5 constitute a family of transporters and function in exporting and recycling siderophores (12). Additionally, these transporters have been shown to contribute to drug resistance by efflux mechanism (8, 23). We hypothesized that the mutations mapping to MSMEG_1380 would result in de-repression of the operon, eventually conferring chrysomycin A resistance. The chrysomycin A resistant strains showed severe growth retardation, possibly attributed to the multiple mutations in the genome, which could be synthetically deleterious (Fig.3A). Therefore, the antibiotic susceptibility assays could not be performed on the resistant colonies. We explored an alternate approach of expressing either the individual genes or the entire operon using a mycobacterial constitutive promoter P_{hsp}. Interestingly, transformants of *M. smegmatis* harboring either *MSMEG_1382* or the entire operon displayed delayed growth on 7H10 plates in comparison to transformants of *MSMEG_1381* indicating over-expression of *MSMEG_1382* either individually or with *MSMEG_1381* negatively impacted bacterial growth (Fig.3B).

Expression of membrane transporters either individually or in operons confers multiple drug resistance.

To further validate if the expression of the transporters is sufficient to confer resistance to chrysomycin A, we determined the minimal inhibitory concentration (MIC) of the strains expressing either of the genes individually or the entire operon. We observed that expression of either *MSMEG_1381* or *MSMEG_1382* alone was sufficient to increase the MIC of *M. smegmatis* to Chrysomycin A by two folds (1.25 µg/mL to 2.5 µg/mL) (Table-2). Membrane transporters and efflux pumps often display the ability to transport a diverse group of molecules (24). Therefore, we tested if the recombinant strains expressing either MSMEG_1381, MSMEG_1382, or the entire operon confer resistance to other first-line/ second-line anti-TB drugs such as isoniazid, ethambutol, and rifampicin. Since the RND

family of transporters efflux xenobiotic molecules, we also tested the strains for ethidium bromide resistance. Strains expressing MmpS5 or MmpL5 displayed increased resistance to ethambutol and isoniazid to 1 μg/mL and 20 μg/mL respectively which is an increase of $\geq$ 2X MIC of WT (0.5 μg/mL and 10 μg/mL)   while there was no difference in the MIC to ciprofloxacin, rifampicin, and ethidium bromide (Table-2). Interestingly, the expression of the entire operon resulted in higher MIC to both isoniazid (40 μg/mL) and ethambutol (2 μg/mL) which is 4X MIC of WT strain. In comparison, the MIC of either the MSMEG_1381 or the MSMEG_1382 over-expression strains was 20 μg/mL or 1 μg/mL for isoniazid and ethambutol respectively (Table-2). In summary, over-expression of efflux pump components resulted in a multidrug resistance phenotype and over-expression of the entire operon augmented the resistance phenotype in comparison to individual proteins.

Molecular interaction of antibiotics with MSMEG_1382

In silico modelling and analyzing of the structure of MSMEG_1382 revealed that the protein contains two distinct tunnels- a wider central tunnel spanning the region of the inner membrane and, a narrow-accessory tunnel facilitating the exit of molecules to periplasmic space (marked as yellow arrows in the structure of MSMEG_1382 in Fig.4A). Therefore, it is hypothesized that the molecules that pass through both the tunnels can interact in the accessory tunnel as the diameter of the tunnel gets reduced. Molecular docking was performed using the site closer to the junction of the accessory tunnel and central one. The docking showed three different binding pockets to which different antibiotics (isoniazid, ethambutol, chrysomycin A, streptomycin , ciprofloxacin, and rifampicin) interact. Isoniazid and ethambutol bind at the start of the accessory tunnel (amino acid chains; 433-446; 159-160) (Fig. 4B and Fig.4C), while ciprofloxacin and rifampicin interact with the amino acids of the central tunnel (amino acid chains; 443-449; 417-420; 164-167) (Fig. 4F and Fig. 4G and Supplementary Table S1). Chrysomycin A and streptomycin are found interacting near the central and accessory tunnel (amino acid chains; 159-160; 445-449; 762-763). Although chrysomycin A has the advantage of a planar coumarin ring and may get efluxed

out, streptomycin may not pass through the accessory tunnel because of its bulkier side chains and deeper interacting pockets in the central tunnel (amino acid chain; 417-418) (Fig. 4D and Fig. 4E). Accordingly, the MmpL overexpressing strains showed a 2-fold increased MIC against ethambutol, isoniazid, and chrysomycin A while MIC remained unchanged against ciprofloxacin and rifampicin (Table-2). Thus, the docking results agree with the observed differences in drug susceptibility.

MSMEG_1381 and MSMEG_1382 belong to the RND family of efflux transporters

Although uncharacterized, MSMEG_1381 and MSMEG_1382 are annotated to encode membrane transporter protein MmpS5 and MmpL5, respectively (https://mycobrowser.epfl.ch/). The MmpL group of proteins belongs to RND permease family and has been implicated in drug resistance (8, 14). While a single gene has been annotated for *mmpS5* (Rv0677c) and *mmpL5* (Rv0676c) in *M. tuberculosis*, there are three proteins annotated as *mmpS5* and *mmpl5* in *M. smegmatis*. To further investigate the potential relatedness of this multi-gene family, we performed a multiple sequence alignment of the four proteins of interest. The alignment demonstrates the strong similarity between the MSMEG_0226 and MSMEG_3495 encoding MmpS5 (91%), indicating a potential duplication. These proteins also shared higher sequence similarity with *M. tuberculosis* MmpS5 (Rv0677) ~60% (Fig. 5B, panel i). Similarly, in the case of MmpL5, the extent of similarity between MSMEG_0225 and MSMEG_3496 was greater (83%) and ~70% with *M. tuberculosis* protein Rv0676 (Fig. 5B panel ii). However, the MSMEG_1381 and MSMEG_1382 shared the least sequence similarity of 55% and 63%, respectively, with the annotated MmpS5 and MmpL5 protein of *M. tuberculosis*. Surprisingly, we observed a high degree of sequence divergence between the MSMEG_1382 and the other *M. smegmatis* proteins, indicating that MSMEG_1381 and MSMEG_1382 were more distantly related to the other *M. smegmatis* MmpS5 and MmpL5 proteins. This was further confirmed by phylogenetic tree analysis constructed using the amino acid sequences of the MSMEG_0225/0226, MSMEG_3495/3496, MSMEG_1381/1382 with Rv0676/0677, similar

topologies were found in the two trees with somewhat congruent phylogenies. Both trees showed that *M. tuberculosis* protein H37Rv was more distantly related to MSMEG_0226 MSMEG_3495 than MSMEG_1382. (Fig. 5A and B)

Discussion:

Previously, Chrysomycin A has been reported to have potent bactericidal activity against drug-resistant clinical strains of *M. tuberculosis* and other Mycobacterium species (19, 20). The goal of the current study was to identify mechanisms that would contribute to drug resistance to Chrysomycin A. We took a forward genetics approach and isolated spontaneous chrysomycin A resistant mutants in *M. smegmatis*. We identified mutations mapping to *MSMEG_1380* gene in all the resistant strains upon whole-genome sequence analysis. In *M. tuberculosis*, Rv0677c, which regulates MSMEG_1380, functions as a negative regulator for an adjacent operon encoding putative membrane transporter (MmpS5~MmpL5 complex). Loss of function mutation of MSMEG_1380 results in de-repression of the Mmp complex resulting in increased resistance to multiple antibiotics (Fig. 6)

All the sequenced isolates (21, 24, and 42) contained mutation mapping close to the predicted DNA binding region of MSMEG_1380, which has been reported to repress the expression of the divergent operon encoding MmpS5 and MmpL5 proteins (25) (Fig. 1B). Phenotypic analysis of the resistant colonies showed that the strains displayed reduced growth compared to the parental strain (Fig. 3A). While this apparent growth defect could be attributed to a synergistic effect of multiple mutations observed in the resistant colonies, delayed appearance of transformants from P_{hsp}~*MSMEG_1381* alone or the entire operon was surprising (Fig. 3B). Although the data presented in our study cannot explain the reduced growth of the over-expression strains, we believe that constitutive expression of the efflux system would burden the cell with unnecessary ATP expenditure compromising growth.

Loss of function mutations in the divergently expressed transcriptional regulator of *mmpS5~mmpL5* operon has been reported to confer antimicrobial resistance compounds such as bedaquiline and clofazimine in *M. tuberculosis* or to thiacetazone in *M. abcessus* (21, 26, 27). The orthologous protein in *M. smegmatis*, MSMEG_1380, functions similarly by acting as a repressor to the *mmpS5~mmpL5* operon and point mutation conferred resistance to Serine-Threonine kinase inhibitor to *M. smegmatis* strain (25). While Masalov et al. reported increased susceptibility of *M. smegmatis* to imidazo tetrazines upon overexpression of MSMEG_1380, we performed the converse experiment of overexpressing either of the Mmp protein in single or the entire operon through the constitutive promoter P_{hsp} and observed increased resistance to multiple antibiotics. Docking of different antibiotics to MmpL5 showed that isoniazid and ethambutol interact with MmpL5 near the exit to the periplasm, suggesting that they could easily pass through the tunnel because of their smaller size. The available structure of MmpL3 that is involved in the transport of trehalose monomycolate (TMM) suggests the presence of three exit gates named G_T, G_F and G_B are present at the top, front, and back of the protein, respectively (28). The authors further proposed that the front exit G_F containing hydrophilic residues could be accessed by the trehalose end of the TMM and could facilitate its movement to the periplasmic space. The accessory channel observed in our modeled structures shares a resemblance to the G_F observed in MmpL3. In the case of chrysomycin A, the planar coumarin structure seems to support the travel across the central and accessory tunnel. However, the ease of passing through the tunnel would be only next to isoniazid and ethambutol. Our docking studies indicated that streptomycin, rifampicin, and ciprofloxacin could be accommodated in deep binding pockets with higher binding affinity. However, the larger molecular size combined with a higher number of hydrogen bond acceptors and donors in these antibiotics would result in more interactions with the amino acid residues in the channel. (Fig.4B-G). The planar structure of these molecules combined with the extensive molecular interactions with the protein would restrict the easy passage through accessory tunnel into the periplasmic

space. We observed similar results in our drug susceptibility assays where the MmpL overexpressing strains were resistant to isoniazid and ethambutol higher than even chrysomycin A. A meagre 2 fold increase in MIC has been observed against chrysomycin A, suggesting that the rate of efflux is slightly lesser than isoniazid and ethambutol. It is noteworthy to mention that sensitivity to ciprofloxacin – a fluoroquinolone drug having similar activity as that chrysomycin A was unchanged when MmpL proteins were expressed either individually or as an operon is known to get effluxed by another efflux pump LfrA (29).

Recently it has been demonstrated that co-expression of MmpS5 facilitates assembly of MmpL5 into a trimeric complex with other accessory proteins in the outer membrane that is competent in drug efflux function(14). However, in our study, expression of MmpS5 alone or MmpL5 alone also contributed to an increase in MIC from 0.5 μg/mL to 1 μg/mL (2-fold) but an expression of the complete operon resulted in the highest MIC to ethambutol upto 2 μg/mL (Table-2). We hypothesize that overexpression of either component of the operon (*mmpS5* or *mmpL5*) can form a heterocomplex with other annotated MmpL5 proteins in *M. smegmatis* (MSMEG_0226 or MSMEG_3496). However, only one copy of annotated *mmpS5* and *mmpL5* is present in the *M. bovis* BCG, as observed by Yamamoto and others (14).

Antimicrobial compounds may themselves induce expression of efflux pump (25, 30) either *in vitro* or *in vivo*, negatively impacting the intended outcome of therapy. Therefore, efflux pump inhibitors as a part of combinatorial antibiotic therapy are attracting considerable interest to treat infections caused by *M. tuberculosis* and other Gram-negative bacteria (10, 31, 32). Molecules such as timcodar and tariquadar inhibit mammalian transporters leading to increased intracellular antibiotic concentration resulting in the efficient killing of intracellular bacteria(33, 34). Inhibiting mycobacterial efflux pump by verapamil or SQ109 in combination can promote antibiotic synergy (35–37), resulting in efficient bactericidal activity. The rationale for using *M. smegmatis* in drug screening is often debated as it is not a pathogen, and its lifestyle does not reflect that of *M. tuberculosis*. However, identification of

mutations in clinical strains of *M. tuberculosis* associated with efflux pumps has been increasingly reported, particularly that of Rv0678, whose ortholog in *M. smegmatis*, which was identified in our study, shows the importance of this bacterium in drug discovery. Identifying a new class of molecules that can inhibit efflux pump will significantly increase the success rate of antibiotic therapy, and engineered strains that express efflux pump like the ones described in our study can be potentially used for deeper screening of lead molecules for their ability to resist being effluxed.

Material and Methods

Bacterial strains and culture conditions

The bacterial strains, plasmids, and oligonucleotides used in the study are listed in Table-3. Strains of *M. smegmatis* were recovered on 7H10 Middlebrook supplemented with 0.5% v/v glycerol and 0.05% v/v Tween 80 plates from glycerol stocks using appropriate antibiotics. For culture in liquid condition, Middlebrook 7H9 medium supplemented with 0.1% v/v glycerol and 0.05% Tween 80 was used. When required, *M. smegmatis* cultures were selected by incorporating kanamycin (50 μg/mL). For cloning and plasmid DNA manipulation, *E. coli* TG1 or JM101 strains were used. *E. coli* strains were cultured in Luria Bertani (LB) broth or LB agar at 37 °C. For selection in *E. coli*, antibiotics with the following concentrations kanamycin (50 μg/mL) and ampicillin (100 μg/mL) were used. All media components were procured from Difco (Maryland, USA). Unless mentioned, all chemicals and reagents were procured from Sigma Aldrich (Missouri, USA).

Isolation of chrysomycin A resistant colonies in M. smegmatis

M. smegmatis mc²155 was used as the fast-growing surrogate model to identify the mutations in spontaneous chrysomycin A resistant mutants. *M. smegmatis* revived on the 7H10 agar from the glycerol stock and incubated and inoculated into 20 mL 7H9 medium at an initial OD_{600} 0.01 and cultured at 37 °C in a shaken incubator till it reached mid-log phase. The culture was harvested, and the bacterial pellet was plated on 7H10 plates containing 12

μg/mL chrysomycin A (Abcam, USA) (6X the MIC) and incubated at 37 °C until resistant colonies appeared. Fifty random colonies were picked up and patched onto a fresh 7H10 agar plate containing chrysomycin A (12 μg/mL). Wild-type *M. smegmatis* and three random chrysomycin A resistant mutants were selected, and their genomic DNA was isolated as described previously described (38) and subjected to whole-genome sequencing.

Electrocompetent cell preparation and transformation

The freshly revived strain of *M. smegmatis* mc²155 was cultured in 2 mL 7H9 medium with tween 80 at 37 °C in shaken condition till saturation. The culture was diluted 1:100 in 100 mL LB medium containing tween and incubated at 37 °C for 14-16 h till the OD_{600} reached ~0.6. The culture was cooled on ice, transferred to 2X50 mL sterile conical tubes, and harvested at 4 °C in an Eppendorf refrigerated centrifuge swing bucket 5804 rotor for 7 min at 4,200g. The culture supernatant was discarded, and the bacterial pellet was resuspended in with an equal volume of ice-cold 10% v/v glycerol. The bacterial suspension was harvested by centrifugation at 4,200g at 4 °C. The washing step was repeated once more, and the final pellet was resuspended in 2 mL of ice-cold 10% glycerol solution. The pellet was resuspended, and 0.1 mL of the suspension was aliquoted into prechilled 1.7 mL sterile microfuge tubes and mixed with 500 ng of pMV262 plasmid harboring either MSMEG_1381, MSMEG_1382, or MSMEG_1381~1382 operon. The mixture was transferred to a prechilled 2 mm sterile electroporation cuvette (BioRad). The electroporation was done in MicroPulser Electroporator (BioRad) using the following setting 2.5 kV, 25 μF, and 1000Ω. The transformed cells were immediately recovered by adding 1 mL of sterile, antibiotic-free 7H9 medium to the cuvette. The contents were transferred to a sterile 1.7 mL microfuge tube and incubated at 37 °C for 3 h. The contents were harvested by centrifuging at 13,000 rpm for 1 min at room temperature, and the pellet was resuspended in 0.1 mL of 7H9 medium and plated on 7H10 plates containing kanamycin. The plates were incubated till colonies appeared.

Homology modeling and Molecular Docking using Schrodinger:

The protein sequences of MSMEG_1380 (UniProt ID A0QS78) and MSMEG_1382 (UniProt ID A0QS80) were retrieved in FASTA format from Mycobrowser and submitted to the I-TASSER web server(39). At least 10 models were generated after considering at least 10 homology three-dimensional protein templates. The 3D models with the highest TM and C-scores values among the predicted structures were used for binding studies. The modeled structures of the protein were imported to Schrodinger software (version 2021-3) in PDB format, and the proteins were prepared using the Protein preparation tool. Briefly, the missing loops were added; over-lapping hydrogen bonds were optimized; the energy minimization was performed along with deletion of water molecules (if any). The prepared protein was analyzed for deep binding pockets using the Sitemap tool. The resulting maps with scores above 1 alone were selected, and a grid was generated with the same. In parallel, the ligands were prepared using LigPrep tool (LigPrep, Schrödinger, LLC, New York, NY, 2021) . The possible states of the ligands at pH 7.0 ± 0.2 were generated using Epik giving rise to 32 different combinations per ligand (40). The prepared ligands and protein were docked using the Glide Ligand docking tool at standard precision with default parameters. The docking poses were recorded along with their docking scores. For protein-DNA docking, 'Patchdock' (https://bioinfo3d.cs.tau.ac.il/PatchDock/php.php) was used, and the resultant structures were submitted to 'Firedock' (https://bioinfo3d.cs.tau.ac.il/FireDock/php.php) for further refinement of the structures (41, 42). To avoid false-positive docking results and to understand the passage of molecules out of the cell, the tunnels in the protein structures were predicted using Mole2.0 online tool (43).

Growth curve analysis

Freshly revived strains of *M. smegmatis* mc^{2}155 and the chrysomycin A resistant isolates 21,24 and 42 were inoculated in 5 mL 7H9 medium in triplicates, and the Optical density at 600 nm (OD_{600}) was adjusted to 0.025. The cultures were incubated in a shaker incubator at

37 ^{o}C at 175 rpm for 48 h. After every 4 h, 0.1 mL aliquot of the bacterial culture was transferred to a sterile optical bottom Nunc microtiter plates. The OD_{600} was measured in a BioRad microplate reader after normalization with an equal volume of sterile 7H9 medium as blank. The mean OD_{600} values ± SD were plotted for each strain using Graphpad Prism v8.0 software.

Whole-genome sequencing of the chrysomycin A resistant strains

Sequencing was performed using the Illumina platform of bridge amplification. Briefly, DNA was quantified by QUBIT 3 Fluorometer using dS DNA HS Dye. The intact DNA (200 ng) was enzymatically fragmented (enzyme in the Illumina sequencing kit was used), and 200-300 bp fragment size was chosen. The DNA fragments undergo end repair wherein the mix converts the overhangs resulting from fragmentation into blunt ends. The end-repair mix's 3' to 5' exonuclease activity removes the 3' overhangs, and polymerase activity fills in the 5' overhangs. To the blunt-ended fragments, adenylation was performed by adding a single 'A' nucleotide to the 3' ends. Loop adapters were ligated and cleaved with the uracil-specific excision reagent (USER) enzyme to the adenylated fragments. The samples were further purified using AM pure beads (New England Biolabs), and PCR then enriched the DNA with 6 cycles using NEB (New England Biolabs). Next, Ultra II Q5 master mix, Illumina universal primer, and sample-specific octamer primers. The amplified products were cleaned up using AM pure beads, and the final DNA library was eluted in 20 μLs of 0.1X TE buffer. One microlitre of the library was used for quantification by QUBIT 3 Fluorometer using dS DNA HS reagent. The fragment analysis was performed on Agilent 2100 Bioanalyzer by loading 1 μL of the library into Agilent DNA 7500 chip. The QC passed libraries were diluted to 2 nM and pooled together. As per the manufacturer's recommendation, the pooled library was further diluted to sequence it on Illumina Hiseq. The Hiseq Control Software was used to set up a 2X150 bp run on Hiseq, and data were demultiplexed using bcl2fastq v2.1.9.The sequence data quality was checked using FastQC and MultiQC software. The data was

checked for base call quality distribution, % bases above Q20, Q30,% GC, and sequencing adapter contamination.

Assembly annotation and variant calling

The QC passed reads were used to assemble the genomes using the Hierarchical Genome Assembly tool (HGA). Contigs shorter than 100 bp were filtered from the assembly. The assembled genomes were annotated using Prokka v1.3 with default parameters (44). The QC passed reads were mapped to the assembled genome of the WT sample using the BWA MEM algorithm with default parameters. The PCR duplicates were marked using sambamamarkdup option. The BAM files were used to call variants using FreeBayes with the ploidy 1 option. The variants were annotated using the snpEff program by considering the prokka predicted protein annotations. The whole-genome sequence data has been deposited at the Sequence Read Archive (SRA) server maintained by NCBI. The project code for the submission is PRJNA821497.

MIC determination by resazurin dye reduction assay

M. smegmatis mc²155 *WT*, and strains harboring the constitutively expressing either MSMEG_1381, MSMEG_1382 or the operon (MSMEG_1381~MSMEG_1382) were freshly revived on 7H10 kanamycin plates. The strains were grown in 3 mL of plain 7H9 or 7H9 kanamycin broth for 48 h. The bacterial density was measured and adjusted to OD_{600} of 0.001 (measured and adjusted to OD_{600} of 0.1 and further diluted 20 times). In a sterile flat-bottom 96-well plate, 100 µl of appropriate 7H9 broth was dispensed in each well. In the last row, 200 µl of 7H9 media containing 2X concentration of individual compounds i.e., chrysomycin A (20 µg/mL), ethambutol (8 µg/mL), isoniazid (160 µg/mL), rifampicin (126 µg/mL), ciprofloxacin (10 µg/mL), Streptomycin and ethidium bromide was added. Serial dilution was performed to establish a continuous 2-fold dilution of the compound. The first well was left untreated and served as antibiotic free control. The diluted bacterial culture (100 µl) of each strain was dispensed into the wells to obtain a final volume of 200 µl/well and a

concomitant dilution of antibiotic by 2X. In each plate, positive control and negative controls were kept. The plates were sealed in plastic bags and incubated at 37° C in a static incubator. After 36 h of incubation, 20 µl of freshly prepared resazurin (0.025%) solution was added to each well, and the plates were incubated in a static incubator at 37° C in a dark condition. The plates were observed after every hour for the reduction of blue-colored resazurin dye to pink-colored end-product. The MIC of the strain was calculated by calculating the lowest drug concentration that prevented the reduction of dye.

Generation of constitutive expression constructs of MSMEG_1381, MSMEG_1382, and MSMEG_1381~1382 operon in M. smegmatis

Oligonucleotides were designed to amplify *MSMEG_1381*, *MSMEG_1382*, or the entire operon (*MSMEG_1381~MSMEG_1382*). The primers were designed using the online Infusion primer design tool (Takara) to contain *BamH*I and *Hind*III in the forward and reverse primers, respectively, along with 10 nucleotides stretch to facilitate infusion cloning. The DNA sequence of *MSMEG_1381* (*mmpS5* ; 417 bp), *MSMEG_1382* (*mmpL5* ; 2904 bp), and the entire operon (3321 bp) were PCR amplified using Q5 DNA polymerase (NEB) in a 50 μl reaction containing 1X reaction buffer, 1X GC enhancer, 20 pmoles each of forward and reverse primers, 200 μM dNTP, ~300 ng of *M. smegmatis mc²155* gDNA and 1U of the enzyme. The PCR reaction involved denaturation at 98°C for 3 min followed by 29 cycles of denaturation at 98°C for 30s, annealing 72°C for 30 s, amplification at 72°C for 1 min followed by a final extension for 5 min at 72°C. The PCR products were separated on 1% TAE gel, and the corresponding amplicons for the individual gene and to the entire operon were eluted from the gel, cloned into pMV261 plasmid previously digested with *BamH*I and *Hind*III by infusion cloning method according to manufacturer's protocol (Takara). The recombinant plasmids, pMV261~P_{hsp}-MSMEG_1381, pMV261~P_{hsp}-MSMEG_1382, and pMV261~P_{hsp}MSMEG_1381~MSMEG_1382 were transformed into *E. coli* TG1 cells. The plasmids were isolated from the colonies selected on the LB agar containing kanamycin.

The recombinant plasmids were confirmed for the presence of insert by restriction digestion analysis and were transformed into *M. smegmatis* mc²155 strain.

Table-1. WGS analysis of chrysomycin A resistant strains and the mutations identified in them. Ref- DNA sequence in the parental WT strain, Alt-alteration

Chrysomycin A	Gene	Ref	Alt	Annotation	Amino acid change
isolate_21	*bm3R*	CGGGGGC	CGGGGGGC	Frameshift variant	Glu5frame shift
	pntA	G	C	missense variant	Gly406Ala
isolate_24	*bm3R*	TGCCCACGCCC	TGCCCACGCCCACGCC	Conservative in-frame	Gly47_Val48insVal
	1	ACG	CACG	insertion	Gly
	pntA	G	C	missense variant	Gly406Ala
isolate_42	*dinB1*	G	A	missense variant	Asp273Asn
	ilvl	A	T	missense variant	Ile420Asn
	bm3R	TGCCCACGCCC	TGCCCACGCCCACGCC	Conservative in-frame	Gly47_Val48insVal
	1	ACG	CACG	insertion	Gly
	pntA	G	C	missense variant	Gly406Ala
	glmM	G	C	missense variant	Glu7Gln

Table-2. MIC values of the strains overexpressing *MSMEG_1381*, *MSMEG_1382*, or *MSMEG_1381~1382* (operon) in comparison with the *M. smegmatis* mc² 155 WT strain as assessed by REMA assay

Antibiotics	MIC (*µg/ml*)			
	M. smegmatis mc² 155 (WT)	WT ~P_{hsp}~MSMEG_1381	WT ~P_{hsp}~MSMEG_1382	WT ~P_{hsp}~MSMEG_1381-MSMEG_1382
Chrysomycin A	1.25	2.5	2.5	2.5
Ethambutol	0.5	1	1	2
isoniazid	10	20	20	40
Rifampicin	3.9	3.9	3.9	3.9
Ciprofloxacin	0.625	0.625	0.625	0.625
Streptomycin	1	1	1	1
Ethidium bromide	3	3	3	3

Table-3 list of strains, plasmids, and oligonucleotides

Strain	Relevant details	Reference
E. coli TG1	Laboratory strain of *E. coli* used for plasmid DNA manipulation F' [traD36 proAB lacIqZ ΔM15] supE thi-1 Δ(lac-proAB) Δ(mcrB-hsdSM) 5(rK - mK -)	
M. smegmatis mc²155	High-efficiency transformation strain of *M. smegmatis*	(45)
mc²155-pMV $P_{hsp\sim}MSMEG\_1381$	mc²155 strain transformed with a kanamycin-resistant replicative plasmid with *MSMEG_1381* gene under *hsp* constitutive promoter for overexpression of the gene.	This study
mc²155-pMV $P_{hsp\sim}MSMEG\_1382$	mc²155 strain transformed with a kanamycin-resistant replicative plasmid with *MSMEG_1382* gene under *hsp* constitutive promoter for overexpression of the gene.	This study
mc²155-pMV $P_{hsp\sim}MSMEG\_1381/1382$	mc²155 strain transformed with a kanamycin-resistant replicative plasmid with *MSMEG_1381~1382* operon under *hsp* constitutive promoter for overexpression of the operon.	This study
Isolate 21 Isolate 24 Isolate 42	Chrysomycin resistant *M. smegmatis* mc²155 strains isolated from 7H10 Chryomycin A plate were employed for whole-genome sequencing.	This study

Plasmid	Relevant details	Reference
pMV $P_{hsp\sim}MSMEG\_1381$	Mycobacterial replicative plasmid with pAL5000 mycobacterial *ori* expressing *MSMEG_1381* from a constitutive P_{hsp} promoter cloned between *BamH*I and *Hind*III sites	This study
pMV $P_{hsp\sim}MSMEG\_1382$	Mycobacterial replicative plasmid with pAL5000 mycobacterial ori expressing *MSMEG_1382* from a constitutive P_{hsp} promoter cloned between *BamH*I and *Hind*III sites	This study
pMV $P_{hsp\sim}MSMEG\_1381\sim1382$	Mycobacterial replicative plasmid with pAL5000 mycobacterial *ori* expressing *MSMEG_1381~1382* from a constitutive P_{hsp} promoter cloned between *BamH*I and *Hind*III sites	This study

Name	Description	Sequence
INFU-MSMEG1381-FP	Primer for cloning *MSMEG_1381* orf	GACAATTGCGGGATCCGTGCTCGGTCGAATCTGGC
INFU-MSMEG1381-RP		CGACATCGATAAGCTTTCATGCTGCCTTCACATAGC
INFU-MSMEG1382-FP	Primer for cloning *MSMEG_1382* orf	GACAATTGCGGGATCCATGAGCGCGCCGACGGAC
INFU-MSMEG1382-RP		CGACATCGATAAGCTTTCAGCTCAGCGCCTCTTCC

Legends to figures

Figure 1. a) Genomic organization of the *MSMEG_1381~MSMEG_1382* operon with the Tet^R family transcriptional regulator MSMEG_1380 expressed divergently b) Nucleotide changes detected in the transcriptional regulator MSMEG_1380 by whole-genome sequence analysis in the chrysomycin resistant isolates 21, 24, and 42 are shown in red adjacent to the corresponding sequence in the wild-type parental strain c) ClustalW alignment of the amino acid residues of MSMEG_1380 of *M. smegmatis* mc^2 155 WT (MSMEG_1380) with the resistant isolates of Chrysomycin A isolate 21, isolate 24 and isolate 42, respectively in which the isolates were showing mutations in the DNA binding region. Color coding of the amino acid residues was assigned using ClustalW's default color scheme. Non-conserved residues in the alignment are specified in " -. "

Figure 2. a) Docked images of i) MSMEG_1380 and ii) MSMEG_1380 mutant with the predicted palindromic sequence (ACCGCGAGCG) found in the upstream region of MSMEG_1380 gene. The original interaction of the helices (yellow and orange) in the wild-type protein with the DNA is perturbed due to duplication of GV at the 50th and 51st positions in the case of mutant MSMEG_1380. Transmembrane domain analysis of b) MSMEG_1381 and c) MSMEG_1382 using Protter. The modeling shows that the MSMEG_1382 has 11 transmembrane domains and extra-cytoplasmic domains extending into the periplasmic region. The MSMEG_1381 does not contain a transmembrane domain and is predicted to be localized in the periplasmic space.

Figure 3. **Over-expression of MSMEG_1382 alone or the entire operon affects growth in *M. smegmatis*** a) Freshly revived cultures of *M. smegmatis* mc^{2}155 and chrysomycin resistant isolates 21, 24, and 43 were cultured in 7H9 medium at 37 ^{o}C. The increase in growth was monitored by measuring OD_{600} in a Bio-Rad plate reader every 4 hrs. The mean values ± SD were plotted using Graphpad Prism V8. Growth profile of chrysomycin A resistant strain was compared to *M. smegmatis* mc^{2}155. b) Electrocompetent cells of *M. smegmatis* mc^{2}155 were prepared and transformed with pMV261 expressing either i)

MSMEG_1381, ii) MSMEG_1382, or iii) the entire operon (Method section) and plated on 7H10 kan plates and incubated at 37 °C. The appearance of colonies on the plate was monitored after 3 days.

Figure 4. Images of MmpL5 with the predicted tunnel (yellow arrow) docked with antibiotics (from left to right)   A) MmpL5 with predicted tunnel B) MmpL5 with Isoniazid (INH), C) MmpL5   with Ethambutol (ETB), D) MmpL5 with chrysomycin A (CA), E) MmpL5 with Streptomycin (STR), F) MmpL5 with ciprofloxacin (CIP), G) MmpL5 with rifampicin (RIF) with representative amino acid interaction map for the respective antibiotics.

Figure 5. Phylogenetic analysis of MSMEG_1381 and MSMEG_1382. a) (**i**) small protein – MSMEG_1381 (MmpS5), (**ii**) large protein–MSMEG_1382 (MmpL5) based on substitution model of Whelan and Goldman (WAG) by MEGA X.0. The confidence values at the nodes were obtained by performing 1000 bootstrap analyses. The scale bars indicate the number of substitutions per 10, 5, and 20 amino acids, respectively. The phylogenetic tree revealed that MSMEG_1382 is very distinctive to MSMEG_0226 and MSMEG_3495, closely related to *M. tuberculosis* H37Rv MmpL5 protein (Rv0676c) b) ClustalW alignment of the proteins of all of three mmpS5/mmpL5 genes from *M. smegmatis* and *Mtb.* The alignment was generated using Jalview 2.10.3. Amino acid residues were color-coded according to ClustalW's default color scheme, with the non-conserved residues in white.

Figure 6. **Mechanism of the evolution of chrysomycin resistance** Under normal conditions, the TetR family transcriptional regulator MSMEG_1380 binds to the promoter of *mmpS5,* preventing transcription of the operon encoding the RND- family transporters MmpL5 (MSMEG_1382) and MmpS5 (MSMEG_1381) (left panel). Spontaneous mutants harboring loss of mutations in *MSMEG_1380* fail to bind to the promoter allowing transcription of the operon. The MmpS5 and MmpL5 form a functional efflux pump resulting in resistance to (isoniazid, ethambutol, and chrysomycin) in *M. smegmatis* (right panel).

References

1. Collaborators, A. R., Murray, C. J., Ikuta, K. S., Sharara, F., Swetschinski, L., Aguilar, G. R., Gray, A., Han, C., Bisignano, C., Rao, P., Wool, E., Johnson, S. C., Browne, A. J., Chipeta, M. G., Fell, F., Hackett, S., Haines-Woodhouse, G., Hamadani, B. H. K., Kumaran, E. A. P., McManigal, B., Agarwal, R., Akech, S., Albertson, S., Amuasi, J., Andrews, J., Aravkin, A., Ashley, E., Bailey, F., Baker, S., Basnyat, B., Bekker, A., Bender, R., Bethou, A., Bielicki, J., Boonkasidecha, S., Bukosia, J., Carvalheiro, C., Castañeda-Orjuela, C., Chansamouth, V., Chaurasia, S., Chiurchiù, S., Chowdhury, F., Cook, A. J., Cooper, B., Cressey, T. R., Criollo-Mora, E., Cunningham, M., Darboe, S., Day, N. P. J., Luca, M. D., Dokova, K., Dramowski, A., Dunachie, S. J., Eckmanns, T., Eibach, D., Emami, A., Feasey, N., Fisher-Pearson, N., Forrest, K., Garrett, D., Gastmeier, P., Giref, A. Z., Greer, R. C., Gupta, V., Haller, S., Haselbeck, A., Hay, S. I., Holm, M., Hopkins, S., Iregbu, K. C., Jacobs, J., Jarovsky, D., Javanmardi, F., Khorana, M., Kissoon, N., Kobeissi, E., Kostyanev, T., Krapp, F., Krumkamp, R., Kumar, A., Kyu, H. H., Lim, C., Limmathurotsakul, D., Loftus, M. J., Lunn, M., Ma, J., Mturi, N., Munera-Huertas, T., Musicha,

P., Mussi-Pinhata, M. M., Nakamura, T., Nanavati, R., Nangia, S., Newton, P., Ngoun, C., Novotney, A., Nwakanma, D., Obiero, C. W., Olivas-Martinez, A., Olliaro, P., Ooko, E., Ortiz-Brizuela, E., Peleg, A. Y., Perrone, C., Plakkal, N., Ponce-de-Leon, A., Raad, M., Ramdin, T., Riddell, A., Roberts, T., Robotham, J. V., Roca, A., Rudd, K. E., Russell, N., Schnall, J., Scott, J. A. G., Shivamallappa, M., Sifuentes-Osornio, J., Steenkeste, N., Stewardson, A. J., Stoeva, T., Tasak, N., Thaiprakong, A., Thwaites, G., Turner, C., Turner, P., Doorn, H. R. van, Velaphi, S., Vongpradith, A., Vu, H., Walsh, T., Waner, S., Wangrangsimakul, T., Wozniak, T., Zheng, P., Sartorius, B., Lopez, A. D., Stergachis, A., Moore, C., Dolecek, C., and Naghavi, M. (2022) Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. *Lancet*. 399, 629–655

2. Li, X.-Z., and Nikaido, H. (2009) Efflux-Mediated Drug Resistance in Bacteria. *Drugs*. 69, 1555–1623

3. Poole, K. (2009) Efflux pumps as antimicrobial resistance mechanisms. *Ann Med*. 39, 162–176

4. Rossi, E. D., Aínsa, J. A., and Riccardi, G. (2006) Role of mycobacterial efflux transporters in drug resistance: an unresolved question. *Fems Microbiol Rev*. 30, 36–52

5. Danilchanka, O., Mailaender, C., and Niederweis, M. (2008) Identification of a Novel Multidrug Efflux Pump of Mycobacterium tuberculosis▽ †. *Antimicrob Agents Ch*. 52, 2503–2511

6. Li, X.-Z., Plésiat, P., and Nikaido, H. (2015) The Challenge of Efflux-Mediated Antibiotic Resistance in Gram-Negative Bacteria. *Clin Microbiol Rev*. 28, 337–418

7. Cole, S. T., Brosch, R., Parkhill, J., Garnier, T., Churcher, C., Harris, D., Gordon, S. V., Eiglmeier, K., Gas, S., Barry, C. E., Tekaia, F., Badcock, K., Basham, D., Brown, D., Chillingworth, T., Connor, R., Davies, R., Devlin, K., Feltwell, T., Gentles, S., Hamlin, N., Holroyd, S., Hornsby, T., Jagels, K., Krogh, A., McLean, J., Moule, S., Murphy, L., Oliver, K., Osborne, J., Quail, M. A., Rajandream, M.-A., Rogers, J., Rutter, S., Seeger, K., Skelton, J., Squares, R., Squares, S., Sulston, J. E., Taylor, K., Whitehead, S., and Barrell, B. G. (1998) Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence. *Nature*. 393, 537–544

8. Viljoen, A., Dubois, V., Girard−Misguich, F., Blaise, M., Herrmann, J., and Kremer, L. (2017) The diverse family of MmpL transporters in mycobacteria: from regulation to antimicrobial developments. *Mol Microbiol*. 104, 889–904

9. Li, G., Zhang, J., Guo, Q., Jiang, Y., Wei, J., Zhao, L., Zhao, X., Lu, J., and Wan, K. (2015) Efflux Pump Gene Expression in Multidrug-Resistant Mycobacterium tuberculosis Clinical Isolates. *Plos One*. 10, e0119013

10. Coelho, T., Machado, D., Couto, I., Maschmann, R., Ramos, D., Groll, A. von, Rossetti, M. L., Silva, P. A., and Viveiros, M. (2015) Enhancement of antibiotic activity by efflux inhibitors against multidrug resistant Mycobacterium tuberculosis clinical isolates from Brazil. *Front Microbiol*. 6, 330

11. Chalut, C. (2016) MmpL transporter-mediated export of cell-wall associated lipids and siderophores in mycobacteria. *Tuberculosis*. 100, 32–45

12. Wells, R. M., Jones, C. M., Xi, Z., Speer, A., Danilchanka, O., Doornbos, K. S., Sun, P., Wu, F., Tian, C., and Niederweis, M. (2013) Discovery of a Siderophore Export System Essential for Virulence of Mycobacterium tuberculosis. *Plos Pathog*. 9, e1003120

13. Pasca, M. R., Guglierame, P., Rossi, E. D., Zara, F., and Riccardi, G. (2005) mmpL7 Gene of Mycobacterium tuberculosis Is Responsible for Isoniazid Efflux in Mycobacterium smegmatis. *Antimicrob Agents Ch*. 49, 4775–4777

14. Yamamoto, K., Nakata, N., Mukai, T., Kawagishi, I., and Ato, M. (2021) Coexpression of MmpS5 and MmpL5 Contributes to Both Efflux Transporter MmpL5 Trimerization and Drug Resistance in Mycobacterium tuberculosis. *Msphere*. 6, e00518-20

15. Deshayes, C., Bach, H., Euphrasie, D., Attarian, R., Coureuil, M., Sougakoff, W., Laval, F., Av−Gay, Y., Daffé, M., Etienne, G., and Reyrat, J. (2010) MmpS4 promotes glycopeptidolipids biosynthesis and export in Mycobacterium smegmatis. *Mol Microbiol*. 78, 989–1003

16. Cuthbertson, L., and Nodwell, J. R. (2013) The TetR Family of Regulators. *Microbiol Mol Biol R*. 77, 440–475

17. Radhakrishnan, A., Kumar, N., Wright, C. C., Chou, T.-H., Tringides, M. L., Bolla, J. R., Lei, H.-T., Rajashankar, K. R., Su, C.-C., Purdy, G. E., and Yu, E. W. (2014) Crystal Structure of the Transcriptional Regulator Rv0678 of Mycobacterium tuberculosis *. *J Biol Chem*. 289, 16526–16540

18. Balhana, R. J. C., Singla, A., Sikder, M. H., Withers, M., and Kendall, S. L. (2015) Global analyses of TetR family transcriptional regulators in mycobacteria indicates conservation across species and diversity in regulated functions. *Bmc Genomics*. 16, 479

19. Muralikrishnan, B., Dan, V. M., Vinodh, J. S., Jamsheena, V., Ramachandran, R., Thomas, S., Dastager, S. G., Kumar, K. S., Lankalapalli, R. S., and Kumar, R. A. (2017) Anti-microbial activity of chrysomycin A produced by Streptomyces sp. against Mycobacterium tuberculosis. *RSC Advances*. 7, 36335–36339

20. Muralikrishnan, B., Edison, L. K., Dusthackeer, A., Jijimole, G. R., Ramachandran, R., Madhavan, A., and Kumar, R. A. (2022) Chrysomycin A inhibits the topoisomerase I of Mycobacterium tuberculosis. *J Antibiotics*. 10.1038/s41429-022-00503-z

21. Ioerger, T. R., O'Malley, T., Liao, R., Guinn, K. M., Hickey, M. J., Mohaideen, N., Murphy, K. C., Boshoff, H. I. M., Mizrahi, V., Rubin, E. J., Sassetti, C. M., Barry, C. E., Sherman, D. R., Parish, T., and Sacchettini, J. C. (2013) Identification of New Drug Targets and Resistance Mechanisms in Mycobacterium tuberculosis. *Plos One*. 8, e75245

22. Milano, A., Pasca, M. R., Provvedi, R., Lucarelli, A. P., Manina, G., Ribeiro, A. L. de J. L., Manganelli, R., and Riccardi, G. (2009) Azole resistance in Mycobacterium tuberculosis is mediated by the MmpS5–MmpL5 efflux system. *Tuberculosis*. 89, 84–90

23. Briffotaux, J., Huang, W., Wang, X., and Gicquel, B. (2017) MmpS5/MmpL5 as an efflux pump in Mycobacterium species. *Tuberculosis*. 107, 13–19

24. Nikaido, H., and Takatsuka, Y. (2009) Mechanisms of RND multidrug efflux pumps. *Biochimica Et Biophysica Acta Bba - Proteins Proteom*. 1794, 769–781

25. Maslov, D. A., Shur, K. V., Vatlin, A. A., and Danilenko, V. N. (2020) MmpS5-MmpL5 Transporters Provide Mycobacterium smegmatis Resistance to imidazo[1,2-b][1,2,4,5]tetrazines. *Pathogens*. 9, 166

26. Hartkoorn, R. C., Uplekar, S., and Cole, S. T. (2014) Cross-Resistance between Clofazimine and Bedaquiline through Upregulation of MmpL5 in Mycobacterium tuberculosis. *Antimicrob Agents Ch*. 58, 2979–2981

27. Halloum, I., Viljoen, A., Khanna, V., Craig, D., Bouchier, C., Brosch, R., Coxon, G., and Kremer, L. (2017) Resistance to Thiacetazone Derivatives Active against Mycobacterium abscessus Involves Mutations in the MmpL5 Transcriptional Repressor MAB_4384. *Antimicrob Agents Ch*. 10.1128/aac.02509-16

28. Zhang, B., Li, J., Yang, X., Wu, L., Zhang, J., Yang, Y., Zhao, Y., Zhang, L., Yang, X., Yang, X., Cheng, X., Liu, Z., Jiang, B., Jiang, H., Guddat, L. W., Yang, H., and Rao, Z. (2019) Crystal Structures of Membrane Transporter MmpL3, an Anti-TB Drug Target. *Cell*. 176, 636-648.e13

29. Takiff, H. E., Cimino, M., Musso, M. C., Weisbrod, T., Martinez, R., Delgado, M. B., Salazar, L., Bloom, B. R., and Jacobs, W. R. (1996) Efflux pump of the proton antiporter family confers low-level fluoroquinolone resistance in Mycobacterium smegmatis. *Proc National Acad Sci*. 93, 362–366

30. Umar, F., Hatta, M., Husain, D. R., Natzir, R., Dwiyanti, R., Junita, A. R., and Primaguna, M. R. (2019) The effect of anti-tuberculosis drugs therapy towards mRNA efflux pump gene expression of Rv1250 in Mycobacterium tuberculosis collected from tuberculosis patients. *New Microbes New Infect*. 32, 100609

31. Brake, L. H. M. te, Knegt, G. J. de, Steenwinkel, J. E. de, Dam, T. J. P. van, Burger, D. M., Russel, F. G. M., Crevel, R. van, Koenderink, J. B., and Aarnoutse, R. E. (2017) The Role of Efflux Pumps in Tuberculosis Treatment and Their Promise as a Target in Drug Development: Unraveling the Black Box. *Annu Rev Pharmacol*. 58, 1–21

32. Marshall, R. L., Lloyd, G. S., Lawler, A. J., Element, S. J., Kaur, J., Ciusa, M. L., Ricci, V., Tschumi, A., Kühne, H., Alderwick, L. J., and Piddock, L. J. V. (2020) New Multidrug Efflux Inhibitors for Gram-Negative Bacteria. *Mbio*. 11, e01340-20

33. Hartkoorn, R. C., Chandler, B., Owen, A., Ward, S. A., Squire, S. B., Back, D. J., and Khoo, S. H. (2007) Differential drug susceptibility of intracellular and extracellular tuberculosis, and the impact of P-glycoprotein. *Tuberculosis*. 87, 248–255

34. Brake, L. H. M. te, Russel, F. G. M., Heuvel, J. J. M. W. van den, Knegt, G. J. de, Steenwinkel, J. E. de, Burger, D. M., Aarnoutse, R. E., and Koenderink, J. B. (2016) Inhibitory potential of tuberculosis drugs on ATP-binding cassette drug transporters. *Tuberculosis*. 96, 150–157

35. Balganesh, M., Dinesh, N., Sharma, S., Kuruppath, S., Nair, A. V., and Sharma, U. (2012) Efflux Pumps of Mycobacterium tuberculosis Play a Significant Role in Antituberculosis Activity of Potential Drug Candidates. *Antimicrob Agents Ch*. 56, 2643–2651

36. Sacksteder, K. A., Protopopova, M., Barry, C. E., Andries, K., and Nacy, C. A. (2012) Discovery and development of SQ109: a new antitubercular drug with a novel mechanism of action. *Future Microbiol*. 7, 823–837

37. Tahlan, K., Wilson, R., Kastrinsky, D. B., Arora, K., Nair, V., Fischer, E., Barnes, S. W., Walker, J. R., Alland, D., Barry, C. E., and Boshoff, H. I. (2012) SQ109 Targets MmpL3, a Membrane Transporter of Trehalose Monomycolate Involved in Mycolic Acid Donation to the Cell Wall Core of Mycobacterium tuberculosis. *Antimicrob Agents Ch*. 56, 1797–1809

38. Vasanthakrishna, M., Kumar, N. V., and Varshney, U. (1997) Characterization of the initiator tRNA gene locus and identification of a strong promoter from Mycobacterium tuberculosis. *Microbiology+*. 143, 3591–3598

39. Roy, A., Kucukural, A., and Zhang, Y. (2010) I-TASSER: a unified platform for automated protein structure and function prediction. *Nat Protoc*. 5, 725–738

40. Shelley, J. C., Cholleti, A., Frye, L. L., Greenwood, J. R., Timlin, M. R., and Uchimaya, M. (2007) Epik: a software program for pKa prediction and protonation state generation for drug-like molecules. *J Comput Aid Mol Des*. 21, 681–691

41. Mashiach, E., Schneidman-Duhovny, D., Andrusier, N., Nussinov, R., and Wolfson, H. J. (2008) FireDock: a web server for fast interaction refinement in molecular docking. *Nucleic Acids Res*. 36, W229–W232

42. Schneidman-Duhovny, D., Inbar, Y., Nussinov, R., and Wolfson, H. J. (2005) PatchDock and SymmDock: servers for rigid and symmetric docking. *Nucleic Acids Res*. 33, W363–W367

43. Yu, X., Cojocaru, V., and Wade, R. C. (2013) Conformational diversity and ligand tunnels of mammalian cytochrome P450s. *Biotechnol Appl Bioc*. 60, 134–145

44. Seemann, T. (2014) Prokka: rapid prokaryotic genome annotation. *Bioinformatics*. 30, 2068–2069

45. Snapper, S. B., Melton, R. E., Mustafa, S., Kieser, T., and Jr, W. R. J. (1990) Isolation and characterization of efficient plasmid transformation mutants of Mycobacterium smegmatis. *Mol Microbiol*. 4, 1911–1919

Figure 1

A

B

Isolate 21	CGGGGGC	CGGGGG**G**C
Isolate 24	TGCCCACGCCCACG	TGCCCACGCCCACG**CCCACG**
Isolate 42	TGCCCACGCCCACG	TGCCCACGCCCACG**CCCACG**

```
Mutant-24    MSAPETPERPLRKDAERNRKRVLEAARELFAAKGLEPNLNDVARHAGVGVGVGTVYRRFA    60
Mutant-42    MSAPETPERPLRKDAERNRKRVLEAARELFAAKGLEPNLNDVARHAGVGVGVGTVYRRFA    60
MSMEG_1380   MSAPETPERPLRKDAERNRKRVLEAARELFAAKGLEPNLNDVARHAGV--GVGTVYRRFA    58
             *********************************************** *********

Mutant-24    TKEELLEAIFEDAMNQLTDLAEEALRKSDSWQGFAWFVEQQCQLTVTDRGLREIAFSKCY   120
Mutant-42    TKEELLEAIFEDAMNQLTDLAEEALRKSDSWQGFAWFVEQQCQLTVTDRGLREIAFSKCY   120
MSMEG_1380   TKEELLEAIFEDAMNQLTDLAEEALRKSDSWQGFAWFVEQQCQLTVTDRGLREIAFSKCY   118
             ************************************************************

Mutant-24    GGDRVKAAQDRLSVVTTELVERAQRDGHLRPGVSATDLPLLALLAGTVTEFAGHVDADLW   180
Mutant-42    GGDRVKAAQDRLSVVTTELVERAQRDGHLRPGVSATDLPLLALLAGTVTEFAGHVDADLW   180
MSMEG_1380   GGDRVKAAQDRLSVVTTELVERAQRDGHLRPGVSATDLPLLALLAGTVTEFAGHVDADLW   178
             ************************************************************

Mutant-24    RRYTSILLEGMRHHPGQEPVAVFALDRPALEAAMRTWEPAGPPSHRPRPPCPPCAT      236
Mutant-42    RRYTSILLEGMRHHPGQEPVAVFALDRPALEAAMRTWEPAGPPSHRPRPPCPPCAT      236
MSMEG_1380   RRYTSILLEGMRHHPGQEPVAVFALDRPALEAAMRTWEPAGPPSHRPRPPCPPCAT      234
             *******************************************************
```

Figure 2

A

i) WT

ii) Mutant

B

C

Figure 3

A

B

i. **MSMEG_1381**   ii. **MSMEG_1382**   iii. Operon

Figure 4

A

Periplasm

Inner membrane

Cytoplasm

Amino acid interaction map

B INH

C ETB

D CA

E STR

**F** CIP

**G** RIF

Figure 5

A

B

Figure 6

1. Randall, C. P., Mariner, K. R., Chopra, I., and O'Neill, A. J. (2012) The Target of Daptomycin Is Absent from Escherichia coli and Other Gram-Negative Pathogens. *Antimicrob Agents Ch*. 57, 637–639

2. Blair, J. M. A., Webber, M. A., Baylay, A. J., Ogbolu, D. O., and Piddock, L. J. V. (2014) Molecular mechanisms of antibiotic resistance. *Nature Reviews Microbiology*. 13, 42–51

3. Partridge, S. R., Kwong, S. M., Firth, N., and Jensen, S. O. (2018) Mobile Genetic Elements Associated with Antimicrobial Resistance. *Clin Microbiol Rev*. 10.1128/cmr.00088-17

4. Bennett, P. M. (2008) Plasmid encoded antibiotic resistance: acquisition and transfer of antibiotic resistance genes in bacteria. *Brit J Pharmacol*. 153, S347–S357

5. Munita, J. M., and Arias, C. A. (2019) Virulence Mechanisms of Bacterial Pathogens. 10.1128/9781555819286.ch17

6. Long, K. S., Poehlsgaard, J., Kehrenberg, C., Schwarz, S., and Vester, B. (2006) The Cfr rRNA Methyltransferase Confers Resistance to Phenicols, Lincosamides, Oxazolidinones, Pleuromutilins, and Streptogramin A Antibiotics. *Antimicrob Agents Ch*. 50, 2500–2505

7. Li, X.-Z., and Nikaido, H. (2009) Efflux-Mediated Drug Resistance in Bacteria. *Drugs*. 69, 1555–1623

8. Poole, K. (2009) Efflux pumps as antimicrobial resistance mechanisms. *Ann Med*. 39, 162–176

9. Rossi, E. D., Aínsa, J. A., and Riccardi, G. (2006) Role of mycobacterial efflux transporters in drug resistance: an unresolved question. *Fems Microbiol Rev*. 30, 36–52

10. Danilchanka, O., Mailaender, C., and Niederweis, M. (2008) Identification of a Novel Multidrug Efflux Pump of Mycobacterium tuberculosis▽ †. *Antimicrob Agents Ch*. 52, 2503–2511

11. Li, X.-Z., Plésiat, P., and Nikaido, H. (2015) The Challenge of Efflux-Mediated Antibiotic Resistance in Gram-Negative Bacteria. *Clin Microbiol Rev*. 28, 337–418

12. Cole, S. T., Brosch, R., Parkhill, J., Garnier, T., Churcher, C., Harris, D., Gordon, S. V., Eiglmeier, K., Gas, S., Barry, C. E., Tekaia, F., Badcock, K., Basham, D., Brown, D., Chillingworth, T., Connor,

R., Davies, R., Devlin, K., Feltwell, T., Gentles, S., Hamlin, N., Holroyd, S., Hornsby, T., Jagels, K., Krogh, A., McLean, J., Moule, S., Murphy, L., Oliver, K., Osborne, J., Quail, M. A., Rajandream, M.-A., Rogers, J., Rutter, S., Seeger, K., Skelton, J., Squares, R., Squares, S., Sulston, J. E., Taylor, K., Whitehead, S., and Barrell, B. G. (1998) Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence. *Nature*. 393, 537–544

13. Viljoen, A., Dubois, V., Girard−Misguich, F., Blaise, M., Herrmann, J., and Kremer, L. (2017) The diverse family of MmpL transporters in mycobacteria: from regulation to antimicrobial developments. *Mol Microbiol*. 104, 889–904

14. Li, G., Zhang, J., Guo, Q., Jiang, Y., Wei, J., Zhao, L., Zhao, X., Lu, J., and Wan, K. (2015) Efflux Pump Gene Expression in Multidrug-Resistant Mycobacterium tuberculosis Clinical Isolates. *Plos One*. 10, e0119013

15. Coelho, T., Machado, D., Couto, I., Maschmann, R., Ramos, D., Groll, A. von, Rossetti, M. L., Silva, P. A., and Viveiros, M. (2015) Enhancement of antibiotic activity by efflux inhibitors against multidrug resistant Mycobacterium tuberculosis clinical isolates from Brazil. *Front Microbiol*. 6, 330

16. Deshayes, C., Bach, H., Euphrasie, D., Attarian, R., Coureuil, M., Sougakoff, W., Laval, F., Av−Gay, Y., Daffé, M., Etienne, G., and Reyrat, J. (2010) MmpS4 promotes glycopeptidolipids biosynthesis and export in Mycobacterium smegmatis. *Mol Microbiol*. 78, 989–1003

17. Ellison, D. W., and Miller, V. L. (2006) Regulation of virulence by members of the MarR/SlyA family. *Curr Opin Microbiol*. 9, 153–159

18. Cuthbertson, L., and Nodwell, J. R. (2013) The TetR Family of Regulators. *Microbiol Mol Biol R*. 77, 440–475

19. Radhakrishnan, A., Kumar, N., Wright, C. C., Chou, T.-H., Tringides, M. L., Bolla, J. R., Lei, H.-T., Rajashankar, K. R., Su, C.-C., Purdy, G. E., and Yu, E. W. (2014) Crystal Structure of the Transcriptional Regulator Rv0678 of Mycobacterium tuberculosis *. *J Biol Chem*. 289, 16526–16540

20. Tam, H.-K., Foong, W. E., Oswald, C., Herrmann, A., Zeng, H., and Pos, K. M. (2021) Allosteric drug transport mechanism of multidrug transporter AcrB. *Nat Commun*. 12, 3889

21. Wells, R. M., Jones, C. M., Xi, Z., Speer, A., Danilchanka, O., Doornbos, K. S., Sun, P., Wu, F., Tian, C., and Niederweis, M. (2013) Discovery of a Siderophore Export System Essential for Virulence of Mycobacterium tuberculosis. *Plos Pathog*. 9, e1003120

22. Briffotaux, J., Huang, W., Wang, X., and Gicquel, B. (2017) MmpS5/MmpL5 as an efflux pump in Mycobacterium species. *Tuberculosis*. 107, 13–19

23. Yamamoto, K., Nakata, N., Mukai, T., Kawagishi, I., and Ato, M. (2021) Coexpression of MmpS5 and MmpL5 Contributes to Both Efflux Transporter MmpL5 Trimerization and Drug Resistance in Mycobacterium tuberculosis. *Msphere*. 6, e00518-20

24. Maslov, D. A., Shur, K. V., Vatlin, A. A., and Danilenko, V. N. (2020) MmpS5-MmpL5 Transporters Provide Mycobacterium smegmatis Resistance to imidazo[1,2-b][1,2,4,5]tetrazines. *Pathogens*. 9, 166

25. Hartkoorn, R. C., Uplekar, S., and Cole, S. T. (2014) Cross-Resistance between Clofazimine and Bedaquiline through Upregulation of MmpL5 in Mycobacterium tuberculosis. *Antimicrob Agents Ch*. 58, 2979–2981

26. Halloum, I., Viljoen, A., Khanna, V., Craig, D., Bouchier, C., Brosch, R., Coxon, G., and Kremer, L. (2017) Resistance to Thiacetazone Derivatives Active against Mycobacterium abscessus Involves Mutations in the MmpL5 Transcriptional Repressor MAB_4384. *Antimicrob Agents Ch*. 10.1128/aac.02509-16

27. Ioerger, T. R., O'Malley, T., Liao, R., Guinn, K. M., Hickey, M. J., Mohaideen, N., Murphy, K. C., Boshoff, H. I. M., Mizrahi, V., Rubin, E. J., Sassetti, C. M., Barry, C. E., Sherman, D. R., Parish, T., and Sacchettini, J. C. (2013) Identification of New Drug Targets and Resistance Mechanisms in Mycobacterium tuberculosis. *Plos One*. 8, e75245

28. Chalut, C. (2016) MmpL transporter-mediated export of cell-wall associated lipids and siderophores in mycobacteria. *Tuberculosis*. 100, 32–45

29. Pasca, M. R., Guglierame, P., Rossi, E. D., Zara, F., and Riccardi, G. (2005) mmpL7 Gene of Mycobacterium tuberculosis Is Responsible for Isoniazid Efflux in Mycobacterium smegmatis. *Antimicrob Agents Ch*. 49, 4775–4777

30. Lee, A., Mao, W., Warren, M. S., Mistry, A., Hoshino, K., Okumura, R., Ishida, H., and Lomovskaya, O. (2000) Interplay between Efflux Pumps May Provide Either Additive or Multiplicative Effects on Drug Resistance. *J Bacteriol*. 182, 3142–3150

31. Brake, L. H. M. te, Knegt, G. J. de, Steenwinkel, J. E. de, Dam, T. J. P. van, Burger, D. M., Russel, F. G. M., Crevel, R. van, Koenderink, J. B., and Aarnoutse, R. E. (2017) The Role of Efflux Pumps in Tuberculosis Treatment and Their Promise as a Target in Drug Development: Unraveling the Black Box. *Annu Rev Pharmacol*. 58, 1–21

32. Marshall, R. L., Lloyd, G. S., Lawler, A. J., Element, S. J., Kaur, J., Ciusa, M. L., Ricci, V., Tschumi, A., Kühne, H., Alderwick, L. J., and Piddock, L. J. V. (2020) New Multidrug Efflux Inhibitors for Gram-Negative Bacteria. *Mbio*. 11, e01340-20

33. Hartkoorn, R. C., Chandler, B., Owen, A., Ward, S. A., Squire, S. B., Back, D. J., and Khoo, S. H. (2007) Differential drug susceptibility of intracellular and extracellular tuberculosis, and the impact of P-glycoprotein. *Tuberculosis*. 87, 248–255

34. Brake, L. H. M. te, Russel, F. G. M., Heuvel, J. J. M. W. van den, Knegt, G. J. de, Steenwinkel, J. E. de, Burger, D. M., Aarnoutse, R. E., and Koenderink, J. B. (2016) Inhibitory potential of tuberculosis drugs on ATP-binding cassette drug transporters. *Tuberculosis*. 96, 150–157

35. Balganesh, M., Dinesh, N., Sharma, S., Kuruppath, S., Nair, A. V., and Sharma, U. (2012) Efflux Pumps of Mycobacterium tuberculosis Play a Significant Role in Antituberculosis Activity of Potential Drug Candidates. *Antimicrob Agents Ch*. 56, 2643–2651

36. Sacksteder, K. A., Protopopova, M., Barry, C. E., Andries, K., and Nacy, C. A. (2012) Discovery and development of SQ109: a new antitubercular drug with a novel mechanism of action. *Future Microbiol*. 7, 823–837

37. Tahlan, K., Wilson, R., Kastrinsky, D. B., Arora, K., Nair, V., Fischer, E., Barnes, S. W., Walker, J. R., Alland, D., Barry, C. E., and Boshoff, H. I. (2012) SQ109 Targets MmpL3, a Membrane Transporter of Trehalose Monomycolate Involved in Mycolic Acid Donation to the Cell Wall Core of Mycobacterium tuberculosis. *Antimicrob Agents Ch*. 56, 1797–1809

38. Umar, F., Hatta, M., Husain, D. R., Natzir, R., Dwiyanti, R., Junita, A. R., and Primaguna, M. R. (2019) The effect of anti-tuberculosis drugs therapy towards mRNA efflux pump gene expression of Rv1250 in Mycobacterium tuberculosis collected from tuberculosis patients. *New Microbes New Infect*. 32, 100609